Brief: Castle Biosciences Announces Publication Of Study For Treatment Of Patients With Cutaneous Melanoma
23/09/2022 12:26
Sept 23 (Reuters) - Castle Biosciences Inc CSTL.O :
* CASTLE BIOSCIENCES ANNOUNCES PUBLICATION OF STUDY
DEMONSTRATING
THE INTEGRATION OF DECISIONDX®-MELANOMA AND CLINICOPATHOLOGIC
FACTORS PROVIDES OPTIMIZED, PERSONALIZED SURVIVAL PROGNOSES FOR
PATIENTS WITH CUTANEOUS MELANOMA
Source text for Eikon: ID:nBwl0XQka
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million